With stock valuations down and out, the timing may be ripe for pharma and big biotech companies to start bargain hunting.
News & Analysis: Clovis Oncology
These three beaten-down cancer stocks could prove to be amazing value plays.
Wall Street is questioning the value and purpose of a recent deal.
Investors need ongoing clinical trials to deliver -- and for the business to rein in expenses.
If you are looking for stocks that offer investors value in an overpriced market, take a gander at this diverse trio.
CLVS earnings call for the period ending June 30, 2019.
The company reported a net loss of $120 million for the second quarter, which was much worse than analysts expected.
CLVS earnings call for the period ending March 31, 2019.
The company decided to discontinue an important clinical trial.
Better-than-expected Rubraca sales were just what investors wanted to see.